On January 20, 2023 CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, reported that a poster presentation highlighting the Phase 1 preliminary results of a recombinant humanized anti-claudin18.2 monoclonal antibody (AB011), as monotherapy and combination therapy, for patients with advanced solid tumors was presented at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium ("ASCO GI"), in San Francisco, California, during January 19-21, 2023 (Press release, Carsgen Therapeutics, JAN 20, 2023, View Source [SID1234626422]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details for the presentation are as follows:
Poster Presentation: A Multicenter, Phase 1 Study of AB011, a Recombinant Humanized Anti-CLDN18.2 Monoclonal Antibody, as Monotherapy and Combined with Capecitabine and Oxaliplatin (CAPOX) in Patients with Advanced Solid Tumors (Abstract #391, Poster #G13)
Presenter: Jin Li MD
Session Title: Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
About AB011
AB011 is a humanized Claudin18.2 monoclonal antibody (mAb) product that has received an investigational new drug (IND) approval from the National Medical Products Administration (NMPA) for the treatment of Claudin18.2 positive solid tumors. CARsgen is conducting a Phase I clinical trial of AB011 for the treatment of Claudin18.2 positive solid tumors in China to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AB011 infusion.